Aim
Atomoxetine is mainly metabolized by CYP2D6 while CYP2C19 plays a
secondary role. It is known that patients carrying genotypes encoding
decreased/absent CYP2D6 metabolism obtain higher atomoxetine
concentrations and are at increased risk of adverse effects. Here, we
aimed to investigate the added effects of reduced-functionCYP2C19 genotype on atomoxetine concentrations in real-world
settings.